FINWIRES · TerminalLIVE
FINWIRES

研究速報:イーストマン・ケミカル、第1四半期決算はまちまちの結果

By

-- 独立系調査会社CFRAは、に対し、以下の調査速報を提供しました。CFRAのアナリストは、以下のように見解をまとめています。イーストマン・ケミカルは、第1四半期の調整後EPSが1.09ドルとなり、前年同期の1.91ドルから減少しました。これは当社の予想である1.37ドルを下回りましたが、市場コンセンサスの1.06ドルは上回りました。売上高は、顧客の在庫調整、消費支出の低迷、中東紛争の影響により、5%減の21億7,700万ドルとなりました。同社は、原材料価格の高騰を相殺するため、約5億ドルの値上げを実施しました。一方、キングスポートのメタノリシス施設は、通期で約3,000万ドルの増益を達成する見込みです。経営陣は、2026年までのコスト削減目標をインフレ調整後で1億2500万ドルから1億5000万ドルに据え置いた。調整後EBITマージンは、販売量の減少と厳しい市場環境により、ほとんどのセグメントで収益性が圧迫されたため、440ベーシスポイント縮小して9.2%となったが、専門事業の販売量/構成比が10%以上増加し、EBITマージンが第4四半期から240ベーシスポイント拡大するなど、四半期ごとに改善が見られた。同社は6億6500万ドルの現金と堅実な投資適格のバランスシートにより、財務上の柔軟性を維持した。

Related Articles

Asia

Telix Says Marketing Authorization Application for Glioma Imaging Candidate Accepted for Review in Europe; Shares Up 3%

Telix Pharmaceuticals (ASX:TLX) said Friday its marketing authorization application filed in Europe for TLX101-Px, its glioma imaging candidate, has been validated and accepted for review, moving into a 210-day active assessment phase.In a statement, the company said it is seeking a broad clinical label, reflective of current clinical practice guidelines, with national marketing authorizations expected to follow shortly after a positive outcome at day 210.The company said it aims to expand patient access to advanced imaging that can distinguish progressive or recurrent glioma from treatment-related changes in both adults and children, with potential for additional future indications.TLX101-Px is also being developed as a patient selection and response assessment tool for Telix's glioblastoma therapy candidate TLX101-Tx, which has been granted orphan drug designation in Europe and the US, per the statement.The phase 3 IPAX-BrIGHT trial of TLX101-Tx in patients with recurrent glioblastoma has started patient dosing internationally and is launching in multiple European countries, the company said.Telix Pharmaceuticals' shares were up 3% in recent Friday trade.

$ASX:TLX
Asia

Zozo's Profit Climbs 6% in Fiscal Year 2025

Zozo's (TYO:3092) profit attributable to owners of the parent rose 5.7% to 47.93 billion yen for the fiscal year 2025 from 45.35 billion yen a year earlier.The shopping mall operator's basic earnings per share increased to 54.11 yen from 50.90 yen a year ago, according to a Tokyo bourse filing on Thursday.Net sales climbed 7.2% to 228.37 billion yen for the full year ended March 31 from 213.13 billion yen in the prior year.The company declared a year-end dividend of 20 yen per share, payable from June 11.For the fiscal year 2026, the company expects attributable profit of 49.7 billion yen, EPS of 56.20 yen, and net sales of 241.9 billion yen.Zozo plans to pay interim and year-end dividends of 20 yen per share each for the year, which is higher than the amount in the year-ago period.

$TYO:3092
Asia

EML Payments Says Regulators Extend Date for Implementation of Required Guarantee Structure

EML Payments (ASX:EML) said the Australian Prudential Regulation Authority (APRA) and Reserve Bank of Australia (RBA) agreed to extend the date for implementation of the required authorized deposit-taking institution guarantee structure, subject to EML Payment Solutions showing "satisfactory progress" towards obtaining the guarantee via periodic reporting, according to a Friday Australian bourse filing.EML Payment Solutions is engaging with several domestic and international financial institutions, as well as legal advisors and trustee service providers, to design the required guarantee structure.The regulators had earlier said that they require the firm to obtain a guarantee from an authorized deposit-taking institution in respect of stored value liabilities for certain EML Payment Solutions programs by Thursday.

$ASX:EML